Michael T Schweizer

List of Publications by Year
in descending order

51 papers	2,002 citations	331670 21 h-index	276875 41 g-index
54 all docs	54 docs citations	54 times ranked	3026 citing authors

#	Article	IF	Citations
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	3.9	15
2	Mismatch repair deficiency and clinical implications in prostate cancer. Prostate, 2022, 82, .	2.3	9
3	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science, 2022, 41, 112-115.	0.4	4
4	BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. JCO Precision Oncology, 2022, , .	3.0	6
5	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	1.9	49
6	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clinical Genitourinary Cancer, 2021, 19, 144-154.	1.9	13
7	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. JAMA Oncology, 2021, 7, 107.	7.1	90
8	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in highâ€risk localized prostate cancer. Prostate, 2021, 81, 418-426.	2.3	8
9	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	1.6	65
10	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6001-6011.	7.0	13
11	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e1-496.e8.	1.6	1
12	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. Clinical Cancer Research, 2021, 27, 6662-6665.	7.0	11
13	Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. JAMA Oncology, 2021, 7, 1378.	7.1	40
14	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate, 2021, 81, 1382-1389.	2.3	10
15	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. JCI Insight, 2021, 6, .	5.0	15
16	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. European Urology, 2020, 77, 144-155.	1.9	46
17	Multimodality Treatment of Bilateral Wilms Tumor in a Pregnant Female. Urology, 2020, 136, e42-e44.	1.0	0
18	â€œMatchingâ€•the â€œMismatchâ€•Repairâ€“Deficient Prostate Cancer with Immunotherapy. Clinical Cancer Research, 2020, 26, 981-983.	7.0	5

#	Article	IF	Citations
19	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. Bladder Cancer, 2020, 6, 71-81.	0.4	16
20	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. Advances in Therapy, 2020, 37, 4910-4929.	2.9	9
21	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. PLoS ONE, 2020, 15, e0239686.	2.5	6
22	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. Journal of Clinical Oncology, 2020, 38, 3740-3742.	1.6	14
23	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. PLoS ONE, 2020, 15, e0233260.	2.5	63
24	CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 382-392.	3.0	51
25	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate, 2019, 79, 701-708.	2.3	18
26	In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cellâ€Based Drug Delivery. Stem Cells Translational Medicine, 2019, 8, 739-740.	3.3	1
27	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology, 2019, 76, 452-458.	1.9	109
28	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine, 2019, 8, 441-449.	3.3	50
29	Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review. Clinical Genitourinary Cancer, 2018, 16, e335-e338.	1.9	4
30	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncology, The, 2018, 19, 76-86.	10.7	149
31	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE, 2018, 13, e0198389.	2.5	86
32	Microsatellite instability in prostate cancer by PCR or next-generation sequencing. , 2018, 6, 29.		96
33	Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian Journal of Andrology, 2018, 20, 405.	1.6	3
34	Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor. Clinical Genitourinary Cancer, 2017, 15, e855-e857.	1.9	26
35	Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. European Urology, 2017, 72, 323-325.	1.9	14
36	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	7.0	122

#	Article	IF	Citations
37	Response: letter to the editor. Expert Opinion on Therapeutic Targets, 2017, 21, 229-229.	3.4	0
38	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers, 2017, 9, 7.	3.7	49
39	Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer. Clinical Advances in Hematology and Oncology, 2017, 15, 785-795.	0.3	19
40	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. Prostate, 2016, 76, 1303-1311.	2.3	21
41	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Medical Oncology, 2016, 33, 44.	2.5	40
42	Bipolar Androgen Therapy for Men With Androgen Ablation NaÃ¯ve Prostate Cancer: Results From the Phase II BATMAN Study. Prostate, 2016, 76, 1218-1226.	2.3	63
43	Targeting intratumoral androgens: statins and beyond. Therapeutic Advances in Medical Oncology, 2016, 8, 388-395.	3.2	7
44	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Medical Oncology, 2016, 33, 77.	2.5	11
45	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget, 2016, 7, 82504-82510.	1.8	64
46	Persistent androgen receptor addiction in castration-resistant prostate cancer. Journal of Hematology and Oncology, 2015, 8, 128.	17.0	59
47	Optimal sequencing of docetaxel and abiraterone in men with metastatic castrationâ€resistant prostate cancer. Prostate, 2015, 75, 1814-1820.	2.3	14
48	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine, 2015, 7, 269ra2.	12.4	205
49	Liquid biopsy: Clues on prostate cancer drug resistance. Science Translational Medicine, 2015, 7, 312fs45.	12.4	17
50	Clinical activity of enzalutamide versus docetaxel in men with castrationâ€resistant prostate cancer progressing after abiraterone. Prostate, 2014, 74, 1278-1285.	2.3	84
51	Immunotherapy for prostate cancer: recent developments and future challenges. Cancer and Metastasis Reviews, 2014, 33, 641-655.	5.9	53